Intravacc develops and improves both viral-based and bacterial-based vaccines. Our scientists have extensive experience in structural and translational microbiology. They apply their knowledge in the vaccine strain design, looking to create the best candidate organisms with the highest immunity, potency and production yield.
Viral vaccine design
Viral vaccine design includes the optimization of both the production cell line and the virus strain; these are used for the development of inactivated virus, live-attenuated virus, and VLP, as well as for alternatives like SRIP, replicons and virus-vectors. The virus strain can calso be rescued from plasmid DNA.
Bacterial vaccine design
Bacterial vaccine design includes inactivated bacteria, toxins, conjugate vaccines, and vaccines against any pathogen using our Outer Membrane Vesicles (OMV) platform.
Antigen selection
We select antigens via bioinformatics or forced evolution, in silico design and subsequent construction. In this process, we take a number of factors into account, including optimization of safety, immunogenicity (such as level of expression and epitope optimization), intrinsic antigen stability, intrinsic safe adjuvant (LPS), conservation of the antigen, and vaccine yield.
GMP readiness
To optimize GMP readiness, bacterial strains are genetically modified without selection markers present in the final production strain. Viral strains are rescued based on their genetic sequence, thereby circumventing the use of clinical isolates that might harbor extraneous viruses.
